Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy

Camlin Tierney*, Janet L. Lathey, Cindy Christopherson, Daniel M. Bettendorf, Richard T. D'Aquila, Scott M. Hammer, David A. Katzenstein

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

42 Scopus citations

Abstract

Human immunodeficiency virus (HIV) type 1 DNA assay data were obtained at baseline from 111 HIV-1-positive subjects who were treated with nucleosides. Higher baseline DNA level, HIV-1 RNA level, and infectious titer were comparably associated with an increased hazard of disease progression (each P < .03). Only DNA level was significantly associated with survival (adjusted hazard ratio for 1 log10 higher level, 3.99; 95% confidence interval, 1.44-11.09; P = .008).

Original languageEnglish (US)
Pages (from-to)144-148
Number of pages5
JournalJournal of Infectious Diseases
Volume187
Issue number1
DOIs
StatePublished - Jan 1 2003

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Prognostic value of baseline human immunodeficiency virus type 1 DNA measurement for disease progression in patients receiving nucleoside therapy'. Together they form a unique fingerprint.

Cite this